These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17597553)

  • 1. Chemical and pharmacological chaperones as new therapeutic agents.
    Loo TW; Clarke DM
    Expert Rev Mol Med; 2007 Jun; 9(16):1-18. PubMed ID: 17597553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease.
    Ulloa-Aguirre A; Janovick JA; Brothers SP; Conn PM
    Traffic; 2004 Nov; 5(11):821-37. PubMed ID: 15479448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological chaperones: potential treatment for conformational diseases.
    Bernier V; Lagacé M; Bichet DG; Bouvier M
    Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cure for traffic jams: small molecule chaperones in the endoplasmic reticulum.
    Römisch K
    Traffic; 2004 Nov; 5(11):815-20. PubMed ID: 15479447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK; Paul S
    FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein misfolding and degradation in genetic diseases.
    Bross P; Corydon TJ; Andresen BS; Jørgensen MM; Bolund L; Gregersen N
    Hum Mutat; 1999; 14(3):186-98. PubMed ID: 10477427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo.
    Conn PM; Ulloa-Aguirre A; Ito J; Janovick JA
    Pharmacol Rev; 2007 Sep; 59(3):225-50. PubMed ID: 17878512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.
    Sawkar AR; Schmitz M; Zimmer KP; Reczek D; Edmunds T; Balch WE; Kelly JW
    ACS Chem Biol; 2006 May; 1(4):235-51. PubMed ID: 17163678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule modulation of cellular chaperones to treat protein misfolding disorders.
    Sloan LA; Fillmore MC; Churcher I
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):666-81. PubMed ID: 19736625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
    Fan JQ
    Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of small molecules that modify the protein folding activity of heat shock protein 70.
    Wisén S; Gestwicki JE
    Anal Biochem; 2008 Mar; 374(2):371-7. PubMed ID: 18191466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of molecular chaperones in human misfolding diseases.
    Broadley SA; Hartl FU
    FEBS Lett; 2009 Aug; 583(16):2647-53. PubMed ID: 19393652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological chaperone action on G-protein-coupled receptors.
    Bernier V; Bichet DG; Bouvier M
    Curr Opin Pharmacol; 2004 Oct; 4(5):528-33. PubMed ID: 15351360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An adaptable standard for protein export from the endoplasmic reticulum.
    Wiseman RL; Powers ET; Buxbaum JN; Kelly JW; Balch WE
    Cell; 2007 Nov; 131(4):809-21. PubMed ID: 18022373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological chaperons: a novel therapeutic approach for genetic diseases].
    Germain DP; Benistan K; Echevarria L
    Med Sci (Paris); 2013; 29(6-7):579-82. PubMed ID: 23859511
    [No Abstract]   [Full Text] [Related]  

  • 16. Correctors promote folding of the CFTR in the endoplasmic reticulum.
    Loo TW; Bartlett MC; Clarke DM
    Biochem J; 2008 Jul; 413(1):29-36. PubMed ID: 18361776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development and the cellular quality control system.
    Conn PM; Janovick JA
    Trends Pharmacol Sci; 2009 May; 30(5):228-33. PubMed ID: 19307028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.
    Fan JQ; Ishii S
    FEBS J; 2007 Oct; 274(19):4962-71. PubMed ID: 17894781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
    Aymami J; Barril X; Rodríguez-Pascau L; Martinell M
    Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reclamation of proteins from the cellular scrap heap.
    Gestwicki JE
    ACS Chem Biol; 2006 May; 1(4):201-3. PubMed ID: 17163671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.